137 related articles for article (PubMed ID: 8622113)
1. Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity.
Jones RN
J Chemother; 1995 Jun; 7 Suppl 2():7-16. PubMed ID: 8622113
[TBL] [Abstract][Full Text] [Related]
2. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups.
Miller GH; Sabatelli FJ; Naples L; Hare RS; Shaw KJ
J Chemother; 1995 Jun; 7 Suppl 2():31-44. PubMed ID: 8622109
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
[TBL] [Abstract][Full Text] [Related]
4. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
5. The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups.
J Chemother; 1995 Jun; 7 Suppl 2():17-30. PubMed ID: 8622108
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
Fritsche TR; Stilwell MG; Jones RN
Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
8. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
[TBL] [Abstract][Full Text] [Related]
9. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
10. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
11. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).
Gales AC; Jones RN; Sader HS
Clin Microbiol Infect; 2006 Apr; 12(4):315-21. PubMed ID: 16524407
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
14. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
Bell JM; Turnidge JD;
Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic use in neonatal sepsis.
Yurdakök M
Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
[TBL] [Abstract][Full Text] [Related]
16. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of nosocomial isolates against a new aminoglycoside isepamicin.
Kapil A; Bali R; Das BK
Indian J Med Res; 2001 Feb; 113():60-2. PubMed ID: 21910285
[TBL] [Abstract][Full Text] [Related]
18. Aminoglycoside resistance in enterococci.
Chow JW
Clin Infect Dis; 2000 Aug; 31(2):586-9. PubMed ID: 10987725
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of non-fermenting Gram-negative isolates to isepamicin in a region with high antibiotic resistance.
Samonis G; Maraki S; Vouloumanou EK; Georgantzi GG; Kofteridis DP; Falagas ME
Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):3191-8. PubMed ID: 22752194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
